You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameOxyphenbutazone
Accession NumberDB03585  (EXPT02440)
TypeSmall Molecule
GroupsWithdrawn
DescriptionOxyphenbutazone was withdrawn from the Canadian market in March 1985 due to concerns regarding bone marrow suppression.
Structure
Thumb
Synonyms
Oxifenbutazona
Oxiphenbutazone
Oxyphenbutazonum
External Identifiers
  • USAF Ge-14
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Oxybutazone Tab 100mgTablet100 mgOralIcn Canada Ltd.1981-12-312005-04-26Canada
Oxyphenbutazone 100mg TabletsTablet100 mgOralLaboratoires Confab IncNot applicableNot applicableCanada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
OxyphenbutazoneNot Available
ReozonNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Oxyphenbutazone monohydrate
7081-38-1
Thumb
  • InChI Key: CNDQSXOVEQXJOE-UHFFFAOYSA-N
  • Monoisotopic Mass: 342.157957196
  • Average Mass: 342.395
DBSALT001825
Categories
UNIIA7D84513GV
CAS number129-20-4
WeightAverage: 324.3737
Monoisotopic: 324.147392516
Chemical FormulaC19H20N2O3
InChI KeyHFHZKZSRXITVMK-UHFFFAOYSA-N
InChI
InChI=1S/C19H20N2O3/c1-2-3-9-17-18(23)20(14-7-5-4-6-8-14)21(19(17)24)15-10-12-16(22)13-11-15/h4-8,10-13,17,22H,2-3,9H2,1H3
IUPAC Name
4-butyl-1-(4-hydroxyphenyl)-2-phenylpyrazolidine-3,5-dione
SMILES
CCCCC1C(=O)N(N(C1=O)C1=CC=C(O)C=C1)C1=CC=CC=C1
Pharmacology
IndicationNot Available
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of action
TargetKindPharmacological actionActionsOrganismUniProt ID
Group IIE secretory phospholipase A2ProteinunknownNot AvailableHumanQ9NZK7 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with 19-norandrostenedione.Experimental, Illicit
4-AndrostenedioneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with 4-Androstenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with 5-androstenedione.Experimental, Illicit
AbciximabOxyphenbutazone may increase the anticoagulant activities of Abciximab.Approved
AcebutololOxyphenbutazone may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Aceclofenac.Approved
AcenocoumarolOxyphenbutazone may increase the anticoagulant activities of Acenocoumarol.Approved
AcetovanilloneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Acetovanillone.Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Oxyphenbutazone.Approved, Vet Approved
AclarubicinOxyphenbutazone may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Oxyphenbutazone.Approved
AlclometasoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Aldosterone.Experimental
Alendronic acidThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Alendronic acid.Approved
AliskirenOxyphenbutazone may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlprenololOxyphenbutazone may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Oxyphenbutazone.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Amcinonide.Approved
AmikacinOxyphenbutazone may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideOxyphenbutazone may decrease the antihypertensive activities of Amiloride.Approved
AmrubicinOxyphenbutazone may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AncrodOxyphenbutazone may increase the anticoagulant activities of Ancrod.Investigational
AnecortaveThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Anecortave.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Anisodamine.Investigational
annamycinOxyphenbutazone may decrease the excretion rate of annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Oxyphenbutazone.Approved
Antithrombin III humanOxyphenbutazone may increase the anticoagulant activities of Antithrombin III human.Approved
Aop200704Oxyphenbutazone may decrease the antihypertensive activities of Aop200704.Investigational
ApixabanOxyphenbutazone may increase the anticoagulant activities of Apixaban.Approved
ApramycinOxyphenbutazone may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Apremilast.Approved, Investigational
ArbekacinOxyphenbutazone may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
ArdeparinOxyphenbutazone may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
ArgatrobanOxyphenbutazone may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololOxyphenbutazone may decrease the antihypertensive activities of Arotinolol.Approved
AtenololOxyphenbutazone may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Azapropazone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Oxyphenbutazone.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Oxyphenbutazone.Approved
BalsalazideOxyphenbutazone may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BecaplerminOxyphenbutazone may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BeclomethasoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Beclomethasone.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololOxyphenbutazone may decrease the antihypertensive activities of Befunolol.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Oxyphenbutazone.Approved, Investigational
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Oxyphenbutazone.Approved
BenoxaprofenThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Benoxaprofen.Withdrawn
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Oxyphenbutazone.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Betamethasone.Approved, Vet Approved
BetaxololOxyphenbutazone may decrease the antihypertensive activities of Betaxolol.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Betulinic Acid.Investigational
BevantololOxyphenbutazone may decrease the antihypertensive activities of Bevantolol.Approved
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Oxyphenbutazone.Approved, Investigational
BisoprololOxyphenbutazone may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinOxyphenbutazone may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololOxyphenbutazone may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Oxyphenbutazone.Approved
BucillamineThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Bucillamine.Investigational
BucindololOxyphenbutazone may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Budesonide.Approved
BufuralolOxyphenbutazone may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumetanideOxyphenbutazone may decrease the diuretic activities of Bumetanide.Approved
BupranololOxyphenbutazone may decrease the antihypertensive activities of Bupranolol.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Oxyphenbutazone.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Oxyphenbutazone.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Oxyphenbutazone.Approved
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Oxyphenbutazone.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Oxyphenbutazone.Approved, Vet Approved, Withdrawn
CarteololOxyphenbutazone may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolOxyphenbutazone may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Oxyphenbutazone.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Celecoxib.Approved, Investigational
CeliprololOxyphenbutazone may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinOxyphenbutazone may increase the anticoagulant activities of Certoparin.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Oxyphenbutazone.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Oxyphenbutazone.Approved, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Oxyphenbutazone.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Oxyphenbutazone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Oxyphenbutazone.Approved
CinoxacinOxyphenbutazone may increase the neuroexcitatory activities of Cinoxacin.Approved, Withdrawn
CiprofloxacinOxyphenbutazone may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
Citric AcidOxyphenbutazone may increase the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Clobetasol propionate.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Clocortolone.Approved
ClodronateThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Clodronate.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Clonixin.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Oxyphenbutazone.Vet Approved
ColesevelamColesevelam can cause a decrease in the absorption of Oxyphenbutazone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Oxyphenbutazone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortisone acetateThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Cortisone acetate.Approved
CurcuminThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Curcumin.Investigational
CyclosporineOxyphenbutazone may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
D-LimoneneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with D-Limonene.Investigational
Dabigatran etexilateOxyphenbutazone may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinOxyphenbutazone may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidOxyphenbutazone may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DaunorubicinOxyphenbutazone may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Deferasirox.Approved, Investigational
dehydroepiandrosterone sulfateThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with dehydroepiandrosterone sulfate.Investigational
DesirudinOxyphenbutazone may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Desmopressin.Approved
DesoximetasoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Oxyphenbutazone.Approved
DextranOxyphenbutazone may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Oxyphenbutazone may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Oxyphenbutazone may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Oxyphenbutazone may increase the anticoagulant activities of Dextran 75.Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Oxyphenbutazone.Approved, Vet Approved
DicoumarolOxyphenbutazone may increase the anticoagulant activities of Dicoumarol.Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Oxyphenbutazone.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Difluocortolone.Approved
DifluprednateThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Oxyphenbutazone.Approved
DihydrostreptomycinOxyphenbutazone may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Oxyphenbutazone.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Oxyphenbutazone.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Oxyphenbutazone.Approved
DoxorubicinOxyphenbutazone may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenoneOxyphenbutazone may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Droxicam.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Duvelisib.Investigational
E6201The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with E6201.Investigational
EbselenThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Ebselen.Investigational
Edetic AcidOxyphenbutazone may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanOxyphenbutazone may increase the anticoagulant activities of Edoxaban.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Oxyphenbutazone.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Oxyphenbutazone.Approved
EnoxacinOxyphenbutazone may increase the neuroexcitatory activities of Enoxacin.Approved
EnoxaparinOxyphenbutazone may increase the anticoagulant activities of Enoxaparin.Approved
EpirizoleThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Epirizole.Approved
EpirubicinOxyphenbutazone may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneOxyphenbutazone may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Oxyphenbutazone.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Oxyphenbutazone.Approved
EquileninThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Equilin.Approved
EsmololOxyphenbutazone may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Estrone sulfate.Approved
Etacrynic acidOxyphenbutazone may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Oxyphenbutazone.Approved, Investigational
Ethyl biscoumacetateOxyphenbutazone may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Etofenamate.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Etoricoxib.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Evening primrose oil.Approved
exisulindThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with exisulind.Investigational
FenbufenThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Fenbufen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Oxyphenbutazone.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Oxyphenbutazone.Vet Approved
FleroxacinOxyphenbutazone may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Oxyphenbutazone.Approved, Withdrawn
fluasteroneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Fludrocortisone.Approved
FluindioneOxyphenbutazone may increase the anticoagulant activities of Fluindione.Investigational
FlumequineOxyphenbutazone may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Flunixin.Vet Approved
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Fluorometholone.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Oxyphenbutazone.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Oxyphenbutazone.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Fluticasone furoate.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Fluticasone Propionate.Approved
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Oxyphenbutazone.Approved, Nutraceutical, Vet Approved
FondaparinuxOxyphenbutazone may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumOxyphenbutazone may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Oxyphenbutazone.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Oxyphenbutazone.Approved
FramycetinOxyphenbutazone may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideOxyphenbutazone may decrease the diuretic activities of Furosemide.Approved, Vet Approved
GabexateOxyphenbutazone may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinOxyphenbutazone may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinOxyphenbutazone may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Oxyphenbutazone.Approved, Withdrawn
GemifloxacinOxyphenbutazone may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinOxyphenbutazone may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinOxyphenbutazone may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1AOxyphenbutazone may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GrepafloxacinOxyphenbutazone may increase the neuroexcitatory activities of Grepafloxacin.Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with HE3286.Investigational
HeparinOxyphenbutazone may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Higenamine.Investigational
HirulogOxyphenbutazone may increase the anticoagulant activities of Hirulog.Experimental
HMPL-004The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with HMPL-004.Investigational
HydralazineOxyphenbutazone may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Oxyphenbutazone.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Oxyphenbutazone.Approved
Hygromycin BOxyphenbutazone may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Oxyphenbutazone.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Icatibant.Approved
IdarubicinOxyphenbutazone may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
idraparinuxOxyphenbutazone may increase the anticoagulant activities of idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Oxyphenbutazone.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Oxyphenbutazone.Investigational
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Oxyphenbutazone.Approved
IndenololOxyphenbutazone may decrease the antihypertensive activities of Indenolol.Withdrawn
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Oxyphenbutazone.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Indoprofen.Withdrawn
INNO-206Oxyphenbutazone may decrease the excretion rate of INNO-206 which could result in a higher serum level.Investigational
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Oxyphenbutazone.Approved, Investigational
IsoxicamThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Isoxicam.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Istaroxime.Investigational
KanamycinOxyphenbutazone may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Kebuzone.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Oxyphenbutazone.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Oxyphenbutazone.Approved
LabetalolOxyphenbutazone may decrease the antihypertensive activities of Labetalol.Approved
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Oxyphenbutazone.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Oxyphenbutazone.Approved, Investigational
LepirudinOxyphenbutazone may increase the anticoagulant activities of Lepirudin.Approved
LevobunololOxyphenbutazone may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinOxyphenbutazone may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Oxyphenbutazone.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Oxyphenbutazone.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Oxyphenbutazone.Approved
LomefloxacinOxyphenbutazone may increase the neuroexcitatory activities of Lomefloxacin.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Lornoxicam.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Oxyphenbutazone.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Loxoprofen.Approved
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Oxyphenbutazone.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Oxyphenbutazone.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Oxyphenbutazone.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Oxyphenbutazone.Approved
ME-609The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Oxyphenbutazone.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Oxyphenbutazone.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Oxyphenbutazone.Approved, Vet Approved
MesalazineOxyphenbutazone may increase the nephrotoxic activities of Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Metamizole.Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Oxyphenbutazone.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Oxyphenbutazone.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Methylprednisolone.Approved, Vet Approved
MetipranololOxyphenbutazone may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Oxyphenbutazone.Approved
MetoprololOxyphenbutazone may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideOxyphenbutazone may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Oxyphenbutazone.Approved
MizoribineThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Oxyphenbutazone.Approved
MometasoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Oxyphenbutazone.Approved
MoxifloxacinOxyphenbutazone may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Oxyphenbutazone.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Oxyphenbutazone.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Nabumetone.Approved
NadololOxyphenbutazone may decrease the antihypertensive activities of Nadolol.Approved
NadroparinOxyphenbutazone may increase the anticoagulant activities of Nadroparin.Approved
NafamostatOxyphenbutazone may increase the anticoagulant activities of Nafamostat.Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Oxyphenbutazone.Approved
Nalidixic AcidOxyphenbutazone may increase the neuroexcitatory activities of Nalidixic Acid.Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Oxyphenbutazone.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with NCX 1022.Investigational
NCX 4016The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with NCX 4016.Investigational
NeamineOxyphenbutazone may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NemonoxacinOxyphenbutazone may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinOxyphenbutazone may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Nepafenac.Approved
NetilmicinOxyphenbutazone may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Niflumic Acid.Approved
NimesulideThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Nimesulide.Approved, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Nitroaspirin.Investigational
NorfloxacinOxyphenbutazone may increase the neuroexcitatory activities of Norfloxacin.Approved
OfloxacinOxyphenbutazone may increase the neuroexcitatory activities of Ofloxacin.Approved
Oleoyl estroneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Oleoyl estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Oxyphenbutazone.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Oxyphenbutazone.Approved
OlsalazineOxyphenbutazone may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Oxyphenbutazone.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Orgotein.Vet Approved
OtamixabanOxyphenbutazone may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Oxyphenbutazone.Approved
OxprenololOxyphenbutazone may decrease the antihypertensive activities of Oxprenolol.Approved
PamidronateThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Parecoxib.Approved
ParomomycinOxyphenbutazone may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
PazufloxacinOxyphenbutazone may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinOxyphenbutazone may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololOxyphenbutazone may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentosan PolysulfateOxyphenbutazone may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Oxyphenbutazone.Approved
PhenindioneOxyphenbutazone may increase the anticoagulant activities of Phenindione.Approved
PhenprocoumonOxyphenbutazone may increase the anticoagulant activities of Phenprocoumon.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Oxyphenbutazone.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Oxyphenbutazone.Approved, Investigational
PindololOxyphenbutazone may decrease the antihypertensive activities of Pindolol.Approved
PirarubicinOxyphenbutazone may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideOxyphenbutazone may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Pirfenidone.Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Oxyphenbutazone.Approved, Investigational
PlicamycinOxyphenbutazone may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Oxyphenbutazone.Approved
PractololOxyphenbutazone may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Oxyphenbutazone.Approved
PrasteroneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Prasterone.Approved, Nutraceutical
PrednicarbateThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Pregnenolone.Experimental
ProbenecidThe serum concentration of Oxyphenbutazone can be increased when it is combined with Probenecid.Approved
PropacetamolThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Propacetamol.Approved
PropranololOxyphenbutazone may decrease the antihypertensive activities of Propranolol.Approved, Investigational
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Oxyphenbutazone.Experimental
Prostaglandin D2The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Oxyphenbutazone.Experimental, Investigational
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Oxyphenbutazone.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Oxyphenbutazone.Vet Approved
Protein COxyphenbutazone may increase the anticoagulant activities of Protein C.Approved
Protein S humanOxyphenbutazone may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeOxyphenbutazone may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinOxyphenbutazone may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with PTC299.Investigational
PuromycinOxyphenbutazone may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Oxyphenbutazone.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Oxyphenbutazone.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Oxyphenbutazone.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Oxyphenbutazone.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Oxyphenbutazone.Experimental, Investigational
ReviparinOxyphenbutazone may increase the anticoagulant activities of Reviparin.Approved
RibostamycinOxyphenbutazone may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Risedronate.Approved, Investigational
RivaroxabanOxyphenbutazone may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Rofecoxib.Investigational, Withdrawn
RosoxacinOxyphenbutazone may increase the neuroexcitatory activities of Rosoxacin.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Oxyphenbutazone.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Oxyphenbutazone.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Oxyphenbutazone.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Oxyphenbutazone.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Oxyphenbutazone.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Seratrodast.Approved, Investigational
SisomicinOxyphenbutazone may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SotalolOxyphenbutazone may decrease the antihypertensive activities of Sotalol.Approved
SP1049COxyphenbutazone may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinOxyphenbutazone may increase the neuroexcitatory activities of Sparfloxacin.Approved
SpectinomycinOxyphenbutazone may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Oxyphenbutazone.Approved
SpironolactoneOxyphenbutazone may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with SRT501.Investigational
StreptomycinOxyphenbutazone may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinOxyphenbutazone may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulfasalazineOxyphenbutazone may increase the nephrotoxic activities of Sulfasalazine.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Oxyphenbutazone.Approved
SulodexideOxyphenbutazone may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Oxyphenbutazone.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Oxyphenbutazone.Approved, Withdrawn
TacrolimusOxyphenbutazone may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Oxyphenbutazone.Approved
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Oxyphenbutazone.Approved
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Oxyphenbutazone.Approved
Technetium tc 99m etidronateThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Technetium tc 99m etidronate.Approved
Technetium Tc-99m MedronateThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Technetium Tc-99m Medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Oxyphenbutazone.Approved, Investigational
TemafloxacinOxyphenbutazone may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Oxyphenbutazone.Experimental, Investigational
TenofovirThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Tenofovir.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Oxyphenbutazone.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Tepoxalin.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Teriflunomide.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Oxyphenbutazone.Approved
TiludronateThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Tiludronate.Approved, Vet Approved
TimololOxyphenbutazone may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Tinoridine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Tixocortol.Approved
TobramycinOxyphenbutazone may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Oxyphenbutazone.Approved
TorasemideOxyphenbutazone may decrease the diuretic activities of Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Oxyphenbutazone.Approved
TranilastThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Tranilast.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Oxyphenbutazone.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Oxyphenbutazone.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Triamcinolone.Approved, Vet Approved
TriamtereneOxyphenbutazone may decrease the antihypertensive activities of Triamterene.Approved
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Oxyphenbutazone.Approved, Vet Approved
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Oxyphenbutazone.Approved
TrovafloxacinOxyphenbutazone may increase the neuroexcitatory activities of Trovafloxacin.Approved, Withdrawn
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Oxyphenbutazone.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Valdecoxib.Investigational, Withdrawn
ValrubicinOxyphenbutazone may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Oxyphenbutazone.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Oxyphenbutazone.Approved
WarfarinOxyphenbutazone may increase the anticoagulant activities of Warfarin.Approved
XimelagatranOxyphenbutazone may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
Ym150Oxyphenbutazone may increase the anticoagulant activities of Ym150.Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Zaltoprofen.Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Oxyphenbutazone.Approved, Investigational, Withdrawn
Zoledronic acidThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Zomepirac.Withdrawn
ZorubicinOxyphenbutazone may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food Interactions
  • Take with food to reduce irritation.
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesS01BC02M01AA03M02AA04
AHFS CodesNot Available
PDB Entries
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9238
Caco-2 permeable+0.5303
P-glycoprotein substrateNon-substrate0.7216
P-glycoprotein inhibitor INon-inhibitor0.7803
P-glycoprotein inhibitor IIInhibitor0.6587
Renal organic cation transporterNon-inhibitor0.8981
CYP450 2C9 substrateNon-substrate0.6167
CYP450 2D6 substrateNon-substrate0.8844
CYP450 3A4 substrateNon-substrate0.5538
CYP450 1A2 substrateInhibitor0.7253
CYP450 2C9 inhibitorInhibitor0.5
CYP450 2D6 inhibitorNon-inhibitor0.923
CYP450 2C19 inhibitorNon-inhibitor0.9035
CYP450 3A4 inhibitorInhibitor0.796
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6021
Ames testAMES toxic0.9107
CarcinogenicityNon-carcinogens0.7686
BiodegradationNot ready biodegradable0.9847
Rat acute toxicity2.9626 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9507
hERG inhibition (predictor II)Non-inhibitor0.924
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
TabletOral100 mg
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point96 °CPhysProp
water solubility60 mg/L (at 30 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP2.72HANSCH,C ET AL. (1995)
logS-3.73ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.256 mg/mLALOGPS
logP2.79ALOGPS
logP3.83ChemAxon
logS-3.1ALOGPS
pKa (Strongest Acidic)4.87ChemAxon
pKa (Strongest Basic)-6ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area60.85 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity90.74 m3·mol-1ChemAxon
Polarizability35.14 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
ClassificationNot classified

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Phospholipase a2 activity
Specific Function:
PA2 catalyzes the calcium-dependent hydrolysis of the 2-acyl groups in 3-sn-phosphoglycerides. Has a preference for arachidonic-containing phospholipids.
Gene Name:
PLA2G2E
Uniprot ID:
Q9NZK7
Molecular Weight:
15988.525 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da
References
  1. Bertucci C, Wainer IW: Improved chromatographic performance of a modified human albumin based stationary phase. Chirality. 1997;9(4):335-40. [PubMed:9275312 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one molecule of endogenous dicarboxylic acid (glutarate, ketoglutarate, etc). Mediates the sodium-independent uptake of 2,3-dimercapto-1-propanesulfonic acid (DMPS) (By similarity). Mediates the sodium-in...
Gene Name:
SLC22A6
Uniprot ID:
Q4U2R8
Molecular Weight:
61815.78 Da
References
  1. Apiwattanakul N, Sekine T, Chairoungdua A, Kanai Y, Nakajima N, Sophasan S, Endou H: Transport properties of nonsteroidal anti-inflammatory drugs by organic anion transporter 1 expressed in Xenopus laevis oocytes. Mol Pharmacol. 1999 May;55(5):847-54. [PubMed:10220563 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23